These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 30657951

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C, Stark R, Limberg N, Rodrigues J, Cordato D, Schwartz R, Jukic R.
    J Headache Pain; 2019 Jul 15; 20(1):81. PubMed ID: 31307383
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database.
    Hepp Z, Rosen NL, Gillard PG, Varon SF, Mathew N, Dodick DW.
    Cephalalgia; 2016 Aug 15; 36(9):862-74. PubMed ID: 26692400
    [Abstract] [Full Text] [Related]

  • 25. OnabotulinumtoxinA in chronic migraine: long-term efficacy in a prophylactic medication free cohort.
    Schiano di Cola F, Pari E, Caratozzolo S, Mancinelli C, Liberini P, Rao R, Padovani A.
    Neurol Sci; 2018 Jun 15; 39(Suppl 1):159-160. PubMed ID: 29904848
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.
    Lipton RB, Rosen NL, Ailani J, DeGryse RE, Gillard PJ, Varon SF.
    Cephalalgia; 2016 Aug 15; 36(9):899-908. PubMed ID: 27288354
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. IncobotulinumtoxinA for Migraine: A Retrospective Case Series.
    Kazerooni R, Lim J, Ashley Blake P, Lessig S.
    Clin Ther; 2015 Aug 15; 37(8):1860-4. PubMed ID: 26166734
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Botulinum toxin A in chronic refractory migraine: premarketing experience].
    Álvaro-González LC, Fernández-García JM, Aranzábal-Alustiza I, Castillo-Calvo B, Iriondo-Etxenagusia I, Rodríguez-Antigüedad A.
    Rev Neurol; 2012 Oct 01; 55(7):385-91. PubMed ID: 23011856
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Onabotulinumtoxin A (BOTOX®) for ProphylaCTIC Treatment of Pediatric Migraine: A Retrospective Longitudinal Analysis.
    Shah S, Calderon MD, Wu W, Grant J, Rinehart J.
    J Child Neurol; 2018 Aug 01; 33(9):580-586. PubMed ID: 29877131
    [Abstract] [Full Text] [Related]

  • 39. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.
    Davies B, Gaul C, Martelletti P, García-Moncó JC, Brown S.
    J Headache Pain; 2017 Sep 06; 18(1):93. PubMed ID: 28879545
    [Abstract] [Full Text] [Related]

  • 40. Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A?
    Butera C, Colombo B, Bianchi F, Cursi M, Messina R, Amadio S, Guerriero R, Comi G, Del Carro U.
    Neurol Sci; 2016 Oct 06; 37(10):1701-6. PubMed ID: 27395386
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.